🎉 M&A multiples are live!
Check it out!

Shield Therapeutics Valuation Multiples

Discover revenue and EBITDA valuation multiples for Shield Therapeutics and similar public comparables like Pharming, Galapagos, and Benevolent AI.

Shield Therapeutics Overview

About Shield Therapeutics

Shield Therapeutics PLC is a commercial stage specialty pharmaceutical company focused on the development and commercialization of late-stage, hospital-focused pharmaceuticals that address areas of high unmet medical need. The company's operating segments are based on key products including PT20 and Feraccru, involves development and commercialisation of the Group’s main Feraccru product, and PT20 is used in treating hyperphosphatemia, which is in its last stage of completion. The company generates maximum revenue from the Feraccru segment.


Founded

2015

HQ

United Kingdom of Great Britain and Northern Ireland
Employees

73

Financials

LTM Revenue $29.6M

LTM EBITDA -$15.0M

EV

$48.0M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Shield Therapeutics Financials

Shield Therapeutics has a last 12-month revenue of $29.6M and a last 12-month EBITDA of -$15.0M.

In the most recent fiscal year, Shield Therapeutics achieved revenue of $16.8M and an EBITDA of -$39.0M.

Shield Therapeutics expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Shield Therapeutics valuation multiples based on analyst estimates

Shield Therapeutics P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $16.8M $31.4M XXX XXX XXX
Gross Profit $0.9M $3.1M XXX XXX XXX
Gross Margin 6% 10% XXX XXX XXX
EBITDA -$39.0M -$23.2M XXX XXX XXX
EBITDA Margin -231% -74% XXX XXX XXX
Net Profit -$33.6M -$63.0M XXX XXX XXX
Net Margin -199% -200% XXX XXX XXX
Net Debt n/a $5.0M XXX XXX XXX

Financial data powered by Morningstar, Inc.

Shield Therapeutics Stock Performance

As of April 15, 2025, Shield Therapeutics's stock price is GBP 0 (or $0).

Shield Therapeutics has current market cap of GBP 28.1M (or $36.2M), and EV of GBP 37.3M (or $48.0M).

See Shield Therapeutics trading valuation data

Shield Therapeutics Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$48.0M $36.2M XXX XXX XXX XXX $-0.03

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Shield Therapeutics Valuation Multiples

As of April 15, 2025, Shield Therapeutics has market cap of $36.2M and EV of $48.0M.

Shield Therapeutics's trades at 1.3x LTM EV/Revenue multiple, and -2.5x LTM EBITDA.

Analysts estimate Shield Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Shield Therapeutics and 10K+ public comps

Shield Therapeutics Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $48.0M XXX XXX XXX
EV/Revenue 1.5x XXX XXX XXX
EV/EBITDA -2.1x XXX XXX XXX
P/E -1.3x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF -2.6x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Shield Therapeutics Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Shield Therapeutics Valuation Multiples

Shield Therapeutics's NTM/LTM revenue growth is 63%

Shield Therapeutics's revenue per employee for the last fiscal year averaged $0.2M, while opex per employee averaged $0.6M for the same period.

Over next 12 months, Shield Therapeutics's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Shield Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Shield Therapeutics and other 10K+ public comps

Shield Therapeutics Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth 87% XXX XXX XXX XXX
EBITDA Margin -74% XXX XXX XXX XXX
EBITDA Growth -40% XXX XXX XXX XXX
Rule of 40 (SaaS-only) -11% XXX XXX XXX XXX
Revenue per Employee $0.2M XXX XXX XXX XXX
Opex per Employee $0.6M XXX XXX XXX XXX
S&M Expenses to Revenue 166% XXX XXX XXX XXX
G&A Expenses to Revenue 116% XXX XXX XXX XXX
R&D Expenses to Revenue 14% XXX XXX XXX XXX
Opex to Revenue 270% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Shield Therapeutics Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Shield Therapeutics M&A and Investment Activity

Shield Therapeutics acquired  XXX companies to date.

Last acquisition by Shield Therapeutics was  XXXXXXXX, XXXXX XXXXX XXXXXX . Shield Therapeutics acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Shield Therapeutics

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Shield Therapeutics

When was Shield Therapeutics founded? Shield Therapeutics was founded in 2015.
Where is Shield Therapeutics headquartered? Shield Therapeutics is headquartered in United Kingdom of Great Britain and Northern Ireland.
How many employees does Shield Therapeutics have? As of today, Shield Therapeutics has 73 employees.
Who is the CEO of Shield Therapeutics? Shield Therapeutics's CEO is Mr. Karl Anders Lundstrom.
Is Shield Therapeutics publicy listed? Yes, Shield Therapeutics is a public company listed on LON.
What is the stock symbol of Shield Therapeutics? Shield Therapeutics trades under STX ticker.
When did Shield Therapeutics go public? Shield Therapeutics went public in 2016.
Who are competitors of Shield Therapeutics? Similar companies to Shield Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Shield Therapeutics? Shield Therapeutics's current market cap is $36.2M
What is the current revenue of Shield Therapeutics? Shield Therapeutics's last 12-month revenue is $29.6M.
What is the current EBITDA of Shield Therapeutics? Shield Therapeutics's last 12-month EBITDA is -$15.0M.
What is the current EV/Revenue multiple of Shield Therapeutics? Current revenue multiple of Shield Therapeutics is 1.3x.
What is the current EV/EBITDA multiple of Shield Therapeutics? Current EBITDA multiple of Shield Therapeutics is -2.5x.
What is the current revenue growth of Shield Therapeutics? Shield Therapeutics revenue growth between 2023 and 2024 was 87%.
Is Shield Therapeutics profitable? Yes, Shield Therapeutics is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.